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The monitoring of the efficacy of anti-retroviral therapy (ART) is becoming an important issue in the developing world. The current use of
CD4 counts, plasma viral loads, and monitoring of drug-resistant viruses are at present either uninformative or costly. Thus, more new cost-
effective and practical techniques need to be established and implemented. Towards this goal, our lab has carried out studies on the potential
use of CD38 frequency and density expression by flow analysis as a means to assess the efficacy of ART. Results of our studies using whole
blood sample from normal healthy donors indicate that CD38 is expressed by a high frequency of not only CD4+ and CD8+ T cells but also
most hematopoietic cell lineages analyzed. Detailed studies of CD38 expression along with other cell surface markers using whole blood
sample from HIV-1-infected patients showed that the most discriminating change was the increased frequency and density of CD38
expression by CD3+CD8+ T cells. Of importance was our preliminary finding that a reversal of the increased frequency and density of CD38
expression by CD8+ T cells only appeared in the whole blood sample from patients who were responders to ART but not those who were
drug failures. These initial data provide a platform and incentive for larger cohort studies including prospective pre- and post-ART for the
institution of such monitoring techniques in resource limited settings.
D 2005 Elsevier Inc. All rights reserved.Keywords: CD38; HIV; Flow cytometry; Drug monitoringIntroduction
HIV infection continues to be a major public health
problem in Thailand with approximately a million indi-
viduals that have been infected by the end of 2003 and so
far with greater than 450,000 deaths associated with HIV/
AIDS (Thai Working Group on HIV/AIDS Projection,
2003). It is also currently estimated that there are
>600,000 Thai’s living with HIV-1 infection who will
require anti-retroviral therapy (ART) at some time point.0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2005.07.018
* Corresponding author.
E-mail address: grkpy@mahidol.ac.th (K. Pattanapanyasat).As elsewhere in the world but particularly so in a
developing country such as Thailand, the health care
system is under increasing pressure to operate cost-
effectively. ART available in the Western countries is too
expensive for common Thai citizens which prompted the
Government Pharmaceutical Organization of Thailand at
the encouragement of the Royal Thai Government to
produce generic anti-retroviral drugs. It has been estimated
that only 13,000 HIV-1-infected Thai patients with a CD4
count <200 received the generic formulation of stavudine,
lamivudine, and nevirapine (termed GPO-Vir) since 2003
and the plans are to make such ART available for an
additional 50,000 HIV-1-infected Thai patients by the end
of 2005 at a cost of US$1.00 per day. However, even such05) 238 – 247
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Asian and African countries and dictate a need to identify
those patients that do not benefit from such therapy (drug
failures) in efforts to maximize the benefit for others who
could benefit from such therapy. Thus, a cost-effective and
practical assay other than cost-prohibitive viral load and
drug-resistant virus monitoring needs to be identified that
could minimally be implemented at regional centers
throughout Thailand to maximize the limited resources
(Pattanapanyasat et al., 2003, 2005).
Flow cytometry is presently being utilized to monitor
CD4 counts in all 60 provincial hospitals in Thailand
accompanied by a centralized government-mandated qual-
ity control program. These thoughts prompted us to
investigate the potential use of CD38 as a marker of cell
activation which could be utilized in conjunction with CD4
counts for the monitoring of drug therapy in HIV-1-
infected Thai patients. The expression of CD38 has been
utilized by a number of laboratories as an activation
marker (Anthony et al., 2003; Benito et al., 2002;
Burgisser et al., 1999; Deeks et al., 2002; Evans et al.,
1998; Hunt et al., 2003; Mildvan et al., 2004; Resino et
al., 2004) and was first reported by Giorgi and Detels
(1989) to be expressed significantly higher on peripheral
blood CD8+ T cells from HIV-infected patients. Later,
results of studies showed that the frequency of CD8+
CD38+ T cells was a good predictor of HIV-1 induced
disease progression (Giorgi et al., 1993, 1999; Liu et al.,
1996, 1997) which correlated well with viral load
(Bouscarat et al., 1999; Liu et al., 1998; Orendi et al.,
1998). The use of CD38 as a predictive marker was further
supported by the finding that levels of this molecule were
markedly decreased in patients following successful
HAART and was closely related to viral load (Tilling et
al., 2002). Of relevance to the studies performed herein
was the finding that there appeared to be a transient
increase in the levels of CD38 expressed in patients on
HAART that correlated with levels of residual virus
replication in these select HIV-infected patients (Benito
et al., 2004) suggesting a direct link between replication of
drug-resistant virus and either a failure to decrease CD38
expression and/or a rebound of CD38 expression. These
studies prompted us to examine whether quantitation of
CD38 expression can be utilized as a surrogate marker for
the effectiveness of ART in the Thai population. The
results of this preliminary study constitute the basis of this
report.Fig. 1. Comparison of CD38 expression using FITC- and PE-conjugated
anti-CD38 monoclonal antibody in healthy adult Thai individuals. CD8+ (a,
c) and CD4+ (b, d) T cells were stained with FITC (black column)- or PE
(open column)-conjugated anti-CD38 monoclonal antibody. CD38 expres-
sion is noted as either the mean frequency (%) of CD38 expressing cells (a,
b) or as the mean density (MFI) of CD38 expression (c, d).Result
High level of CD38 expression in healthy Thai individuals
In efforts to initiate studies on the potential use of CD38
as a marker for the monitoring of the efficacy of ART in
HIV-1 infected patients, a baseline study was first performedto define CD38 expression on 20 normal adult Thai
volunteers. Previously published reports had shown low
levels of CD38 expression on CD4+ or CD8+ cells on
normal healthy individuals with a marked increase in both
the frequency of cells and the level (density) of expression
of this molecule following in vitro cell activation. We thus
decided to first of all compare FITC vs. PE-conjugated anti-
CD38 monoclonal antibody (mAb) reagents to determine
the frequency and density of CD38 expression by CD4+ and
CD8+ T cells in these 20 healthy adult Thai volunteers. All
the values reported below for either the frequency or the
density of cell surface expression are reported as mean T
SD. Interestingly, we found that a very high frequency of
both CD8+ T cells (73.5 T 8.7) and CD4+ T cells expressed
CD38 (74.0 T 5.8) when PE conjugated anti-CD38 mAb
was utilized as compared with data obtained utilizing FITC-
conjugated anti-CD38 mAb which gave values of 7.2 T 3.2
for CD8+ T cells and 18.2 T 5.5 for CD4+ T cells (Figs. 1a
and b). When the densities of CD38 expression were
examined for the same data sets, the mean density of CD38
expression using the PE-conjugated mAb was 315.3 T 106.0
for CD8+ T cells and 530.3 T 104.9 for CD4+ T cells as
compared with only 50.1 T 7.4 for CD8+ T cells and 45.2 T
6.3 for CD4+ T cells when using the FITC-conjugated
antibody (Figs. 1c and d). These data emphasize caution in
the analysis of data on the expression of CD38 which should
take into account the fluorochrome being utilized for the
reported studies. In addition, while all remaining studies
were performed using both FITC- and PE-conjugated anti-
CD38 mAb, only the results with the PE-conjugated reagent
are reported herein for simplification of data analysis. In
efforts to determine the relationship between the expression
of CD38 and another independent marker of cell activation,
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CD38 expression by CD4+ and CD8+ Tcells. The frequency
of CD8+ and CD4+ T cells that co-expressed CD38 and
HLA-DR was 14.5 T 7.0 and 4.4 T 2.5, respectively. These
results suggest that although the frequencies and densities of
CD38 expression using the PE-conjugated anti-CD38 anti-
body on resting CD4+ and CD8+ T cells in the normal Thai
population is high, most of these cells do not co-express
HLA-DR on their cell surface. This was true even when a
PE-conjugated anti-HLA-DR reagent was utilized.
These findings of high levels of CD38 expression by
both CD8+ and CD4+ T lymphocytes in normal blood
donors prompted us to examine the expression of CD38 on
other cell lineages in the same normal donors using the same
PE-conjugated anti-CD38 mAb. Studies were therefore
carried out to examine the frequencies of CD38 expressing
CD19+ B cells, CD56+ NK cells, the TCR gamma–delta+
T cells, and for purposes of control, the total lymphoid cell
lineage. As shown in Fig. 2, a high frequency of CD38
expressing cells was observed in all lymphocyte subsets.
The highest mean frequency of >90% was observed within
the NK cell lineage. These data suggest that the previously
published data on the expression of CD38 on lymphoid cell
lineages need to be re-evaluated based on the fluorochrome
one utilizes for such studies.
CD38 expression in anti-retroviral drug naive HIV-infected
patients
In the light of the above findings, we next conducted a
series of studies on how the results of the above data would
impact on the use of CD38 expression as a marker of HIV
disease and, in particular, its application for the monitoring
of the efficacy of ART. We first compared the frequency and
mean density of expression of CD38 in whole blood
samples from 20 adult HIV-infected patients who had no
prior history of ART with samples from 31 normal adultFig. 2. Expression of CD38 by different lymphoid cell subsets depicted as
mean frequency within each cell lineage. A combination of subset-specific
monoclonal antibodies with PE-conjugated anti-CD38 monoclonal anti-
body was used.Thai volunteers. Fig. 3 demonstrates a representative flow
cytometric profile which compares data on CD38 expres-
sion by CD8+ T cells from 2 healthy individuals and 2
untreated HIV-infected patients and Table 1 lists the mean
values of the CD38 expressing CD4+ and CD8+ T cells
from both HIV-infected patients and normal controls. As
seen, the frequency of CD8+ T cells expressing CD38 was
significantly higher (P = 0.0001) in the 2 HIV-infected
patients (88.9 and 92.4 % with a mean of 89.8 T 5.0 for the
20 patients) than the 2 normal controls (71.4 and 88.2%
with a mean of 70.3 T 11.3 for the 31 normal individuals).
Similarly, the frequency of CD4+ T cells expressing CD38
was also somewhat higher giving a mean value of 79.2 T
11.1 for samples from HIV-1-infected patients (see Table 1)
as compared to 71.6 T 7.8 for the normal controls (P <
0.039). In these same analyses, the mean density of CD38
expression by CD4+ and CD8+ T cells was also determined
and found to be significantly increased (P < 0.0001) in each
of these subsets from the HIV-1-infected patients as
compared to controls (see Table 1).
Although high levels of CD38 expressing cells were
found in healthy Thai individuals, most of these cells did
not express HLA-DR, as shown above. We thus reasoned
that it would be important to examine the relationship
between HLA-DR expression on CD38 expressing CD4+
and CD8+ T cells from HIV-infected patients as compared
with normal individuals. In contrast to normal control
subjects, CD38+ HLA-DR+ co-expressing cells were a
dominant phenotype in HIV-infected patients (see Fig. 3).
The mean frequency of CD38+ HLA-DR+ co-expressing
cells was 57.0 T 13.6 for CD8+ T cells and 29.4 T 23.4 for
CD4+ T cells as compared with 14.5 T 7.0 and 4.4 T 2.5
for CD8+ and CD4+ T cells, respectively, from control
subjects (each giving values of P < 0.0001 when compared
to controls).
CD38 and HLA-DR co-expression by CD8+ T cells
correlates with CD4 count but not viral load
Since the objective of this study was to determine the
potential of using CD38 expression as a marker for disease
progression, a correlation between CD38 expression, CD4
count, and viral load in anti-retroviral drug naı¨ve HIV-
infected patients was performed and the data are shown in
Fig. 4. As seen, whereas there is an inverse correlation
between frequency and density of CD38 expression on
CD8+ T cells and absolute count and/or percentage of CD4+
T cells, there was a direct correlation between frequency and
density of CD38 expression and plasma HIV viral copies/ml
(see Fig. 4). When data on CD38 and HLA-DR co-
expression was examined in samples from HIV-1-infected
patients, whereas there was an inverse correlation between
the frequency of CD8+ T cells that co-expressed HLA-DR
and absolute CD4 count (and/or the percentage of CD4+ T
cells), there was no statistically significant correlation
between the frequency of CD8+ T cells that co-expressed
Fig. 3. Representative profile comparing CD38 expression in CD8+ T cells from 2 healthy individuals (Normal) and 2 untreated HIV-infected subjects (HIV).
Flow cytometry histograms and two-color dot plot for the 4 samples are shown. The frequency of CD38 expressing cells are indicated by the M1 bar of the
histograms whereas the frequency of CD38 + HLA-DR+ co-expressing cells are listed in the upper right quadrant.
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copies/ml (see Fig. 4).
Decreased CD38 expression in anti-retroviral drug-treated
HIV-infected patients
In efforts to determine whether CD38 expression can be
used as a therapeutic marker following ART, we measured
CD38 expression in 23 HIV-infected patients who showed
significant response to ART with stable control of plasma
viremia (viral load <50 copies/ml) after receiving ART. As
shown in Fig. 5a, a slight but statistically significant
decrease in the frequency of CD38 expressing CD8+ T
cells was observed in treated drug responder patients when
compared to untreated HIV-infected patients. Thus, the
frequency of T cells expressing CD38 was 79.2 T 13.0 for
CD8+ T cells and 70.8 T 8.4 for CD4+ T cells in the drug-
treated responder patients as compared with 89.8 T 5.0 forTable 1
Comparison of the relative frequencies (%) and mean density (MFI) of
CD38 expression by CD4+ and CD8+ T cells from HIV-1-infected drug
naı¨ve and normal controls
Source of cells (n) Phenotype CD38 expression
% MFI
Normal (31) CD4 71.6 T 7.8 518.9 T 106.9
HIV-1 (20) CD4 79.2 T 11.1# 885.3 T 2 91.5*
Normal (31) CD8 70.3 T 11.3 312.4 T 94.9
HIV-1 (20) CD8 89.8 T 5.0* 847.4 T 324.1*
Note. *P < 0.0001 when compared with normal, #P < 0.05 when compared
with normal.CD8+ T cells (P = 0.0011) and 79.2 T 11.1 for CD4+ T cells
(P < 0.017) from the untreated patients.
In contrast to the data comparing the frequency of CD8+
and CD4+ T cells that expressed CD38 between treated and
untreated HIV-infected patients where statistically signifi-
cant differences were noted, there was even a greater
difference when we compared the mean density of CD38
expression selectively on CD8+ T cells. Thus, as seen in Fig.
5b, the mean density of CD38 expression on CD8+ T cells
was 475.3 T 411.8 for samples from drug-treated responder
patients as compared with values of 847.4 T 324.1 for CD8+
T cells from untreated HIV-1-infected patients (P < 0.0001).
The density values of CD38 expression by CD4+ T cells
from drug-treated as compared to untreated controls were not
statistically significant. It is important to note, however, that
the values for CD38 expression in the drug-treated responder
HIV-infected patients were still higher than seen in normal
non-HIV-infected subjects and thus do not return back to
normal values at least at the stages that the samples were
tested from this cohort of HIV-infected patients.
The next obvious analyses we performed were to
determine whether values for the co-expression of HLA-
DR with CD38 would provide an even more optimal
discriminatory function between patients receiving ART
and those without drug therapy. As seen in Fig. 5c, the
frequency of CD8+ T cells co-expressing CD38 and HLA-
DR was significantly (P < 0.0001) decreased in the ART
receiving drug responder patients (37.0 T 15.9) as compared
to the non-drug-treated HIV-infected patients (57.0 T 13.6).
The values for CD4+ T cells that co-expressed HLA-DR and
CD38 in the drug-treated responder patients (18.0 T 13.5)
were not significantly different from the untreated patients
Fig. 4. Linear regression analysis of the correlation between CD38 expression in CD8+ T cell and absolute CD4 count, percent CD4, and viral loads in the
group of untreated HIV-infected patients. Correlation between the frequency (%) of CD38 expression (a–c), mean density (MFI) of CD38 expression (d–f),
and the frequency (%) of CD38+ HLA-DR+ co-expression (g– i) is shown.
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HLA-DR and CD38 co-expression on CD8+ T cells as a
monitoring device further increases the sensitivity of the
therapeutic drug monitoring. Unlike data obtained on the
untreated HIV-infected patients, no correlation was noted
between absolute CD4 count, the percentage of CD4+ Tcells
and CD38 expression in the anti-retroviral drug-treated
patients (data not shown).
Comparative analyses of the data from the anti-retroviral
drug-treated vs. untreated patients indicate that whereas a
decrease in the density of CD38 expression and frequency
of CD38/HLA-DR co-expression in anti-retroviral drug-
treated HIV-infected patients can be used as a therapeutic
marker, unfortunately no specific cutoff points could be
established for distinguishing untreated patients from treated
patients. Clearly, either a larger cohort needs to be studied in
order to establish such values or data have to be analyzed on
a per patient basis prior to and following ART.
Increased CD38 expression in anti-retroviral drug-treated
patients who showed virological failure
It is also recognized that inclusion of HIV-1-infected
patients that fail ART in such analyses of CD38 expression byCD8+ Tcells would be very useful for the implementation of
CD38 expression as a therapeutic drugmonitoring tool. Thus,
we measured CD38 expression in 5 HIV-infected patients
who showed virological failure (viral load > 50 copies/ml)
after receiving ARTand compared to patients with successful
ART. As shown in Fig. 5a, a slight but statistically significant
increase in the frequency of CD38 expressing CD8+ T cells
was observed in patients who were classified as ART failures.
Thus, the frequency of T cells expressing CD38 was 93.7 T
4.8 for CD8+ Tcells (P = 0.0053) and 81.0 T 5.7 for CD4+ T
cells (P = 0.0128). A statistically greater significant increase
was observed when we compared the mean density of CD38
expression. As seen in Fig. 5b, the mean density of CD38
expression was 871.8 T 244.3 for CD8+ T cells (P = 0.0030)
and 1041.6 T 384.5 for CD4+ T cells (non-significant) in
samples from patients who were classified as ART failures.
The frequency of CD8+ and CD4+ T cells co-expressing
CD38 and HLA-DR was also significantly increased in ART
treated patients who showed virological failure with values of
55.9 T 14.7 for the CD8+ Tcells (P = 0.0286) and 32.7 T 15.9
for CD4+ Tcells (non-significant) as shown in Fig. 5c. Unlike
data obtained on the ART-treated responder HIV-infected
patients, no significant difference of CD38 expression by
CD4+ and CD8+ T cells was noted between the patients who
Fig. 5. Comparison of CD38 expression in four different groups of subjects.
Healthy individuals (open columns), untreated HIV-infected patients (gray
columns), successful anti-retroviral-treated HIV-infected patients (black
columns), and anti-retroviral-treated HIV-infected patients who showed
virological failure (line columns) are depicted as the mean frequency (%) of
CD38 expression (a), the mean density (MFI) of CD38 expression (b), and
the mean frequency (%) of CD38+ HLA-DR+ co-expression (c) in CD8+
and CD4+ T cells using PE-conjugated anti-CD38 monoclonal antibody.
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shown in Fig. 5.Discussion
Chronic immune activation has been reasoned to be a
significant contributor to disease progression in HIV-1-
infected patients which has prompted the use of the
expression of cell surface activation markers such as
CD38 to monitor disease progression. Results from severalsuch studies have documented a correlation between plasma
viral load and the increased expression of CD38 as a strong
predictor of disease progression (Bouscarat et al., 1999;
Giorgi et al., 1993, 1999; Liu et al., 1996, 1997, 1998;
Orendi et al., 1998). The level of expression of CD38
molecules has been shown to be relatively high in immature
and activated T cells, relatively low in mature and resting
naı¨ve hematopoietic cells, and almost undetectable on
resting memory T cells (Mehta et al., 1996).
In contrast to these previous findings of low expression
on resting cells, the results reported herein show that the
level of CD38 expression depends on the sensitivity of the
fluorochrome being utilized. Thus, unlike the previous
reported studies (Anthony et al., 2003; Benito et al., 2002;
Tilling et al., 2002), results of our studies in healthy subjects
showed a significantly higher frequency of CD38 expres-
sion in both CD8+ and CD4+ T cells when using PE
conjugated anti-CD38 mAb as compared with using FITC
conjugated mAb. It is important to note that the detection of
such differences in the frequencies using a brighter
fluorochrome only applies to molecules that are expressed
at relatively lower levels per cell (<1000 molecules/cell).
Thus, as noted in the data presented herein, the increased
frequencies were only noted when PE-conjugated anti-
CD38 mAb was utilized in conjunction with FITC-
conjugated anti-HLA-DR mAb. Use of PE-conjugated
anti-HLA-DR mAb in conjunction with FITC-conjugated
anti-CD38 mAb did not show any increase in the frequency
of HLA-DR expressing cells. This is because the relative
expression of HLA-DR per cell (>1000 molecules/cell
which is readily detectable using most fluorochrome-
conjugated antibodies including FITC) is significantly
higher than CD38. Thus, use of FITC-conjugated anti-
HLA-DR is sufficient to detect all cells expressing HLA-DR
which is not true for CD38. However, use of PE-conjugated
anti-HLA-DR mAb did increase the density values for this
molecule but not the frequency of cells expressing HLA-
DR. It is also important to note that the high frequencies of
CD38 expressing cells were not restricted to just CD4 and
CD8 cell lineages but were also noted in NK cells, B cells,
and gamma–delta T cells. These data suggest that results of
the studies of cell surface markers particularly those
expressed at relatively lower levels need to be carefully
evaluated in the context of the fluorochrome being utilized
and the sensitivity of the flow cytometer/analyzer being
utilized to acquire the data. A need for standardization is
thus readily apparent. This issue becomes important not
only for research-based studies but also for clinical studies
which rely on such data for clinical decision making.
Flow cytometry has clearly provided a powerful tool in
both clinical diagnostic and research applications. How-
ever, as stated above, an issue that is often ignored
concerns the analysis and interpretation of the data
acquired, especially as it relates to the sensitivity of the
reagent and the flow cytometer being utilized. For clinical
studies, there has always been a need for standardization
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quality control of the reagents and the instruments. For
research purists, there has also been a need to define
expression in more concrete terms. Thus, is the molecule
expressed on the cell surface or not? To make such a
statement requires knowledge as to how many molecules
of a given protein need to be expressed by a given cell for
it to be detectable with the use of appropriate antibodies
and the sensitivity of the instrument being utilized, the
affinity of the antibody for the molecule, the stability of
the interaction between the antibody and its ligand, the
proximal distribution of the molecule on the cell surface,
the ability of the molecule to undergo capping following
ligation of the molecules with the appropriate antibody,
and the state of the cell, i.e., is it resting or activated and
the degree of activation. Thus, this becomes a complex
issue. In this regard, it is important to note that there are a
number of other flow cytometric-based procedures that
have been utilized to increase the sensitivity for the
detection of cell surface molecules. These procedures
include the three-layer amplification technique (Mavrange-
los et al., 2004; Zola et al., 1990), the use of magneto-
fluorescent liposomes (Scheffold et al., 1995), enzymatic
amplification staining (Earnshaw and Osbourn, 1999;
Kaplan and Smith, 2000; Kaplan et al., 2001), and the use
of new fluorophores, fluorescent microspheres, and Quan-
tum dots (Bhalgat et al., 1998; Lidke et al., 2004; Panchuk-
Voloshina et al., 1999). While these methods are clearly
more sensitive for the detection of low-abundance cell
surface molecules, they also have been shown to give
variable results and high nonspecific staining (Mavrangelos
et al., 2004). Some of these procedures are also relatively
impractical for use in the clinical laboratory due to the
complexities within the technique. For example, enzymatic
amplification staining is not only time consuming but it also
requires the use of many different reagents and involves
many steps to be performed during the staining process.
Currently, there are a number of procedures available to
monitor the outcome of ART. These include CD4 counts,
viral load, drug-resistance testing and therapeutic drug
monitoring (TDM). Successful ART refers to therapy that
leads to a stable increase in CD4 counts compared with CD4
counts pre-ART or higher than what is considered to be
protective of AIDS-defining illnesses (>200 cells/Al), a
viral load that is undetectable (clearly based on the
sensitivity of the method employed), the absence of drug
resistance mutants assessed by phenotypic or genotypic
resistance assays, and the maintenance of an effective drug
concentration that provides maximal therapeutic effect with
the least possible toxicity (Frenkel and Tobin, 2004; Grabar
et al., 2000; Rakhmanina et al., 2004). Although these
methods are very useful for the monitoring of patients
receiving ART, each method has some disadvantage which
is reflected by the accuracy of the measurements of the
therapeutic outcome which in some cases make it imprac-
tical for clinical laboratory testing. Thus, treatment failure asdetermined by CD4 counts will be detected relatively late
since no significant change in the level is normally observed
during drug treatment (Deeks et al., 2002; Kaufmann et al.,
1998; Piketty et al., 1998). While viral load can be used to
monitor a success or failure of anti-retroviral treatment, the
cost of viral load measurements remain expensive and
inaccessible to most patients in the developing world
(Stephenson, 2002). A genotypic resistance assay is
currently available only in three teaching hospitals in
Bangkok and TDM is only available at the HIV-NAT
laboratory in Bangkok and each of these are difficult to
implement and deemed impractical.
The above issues prompted a need for defining an
affordable anti-retroviral therapeutic monitoring strategy
and thus was the rationale for the studies reported herein.
Thus, in contrast to previous studies that predominantly
utilized the relative levels of CD38 expression as a
prognostic marker for disease progression in HIV-1-infected
patients, the studies reported herein were conducted in
efforts to evaluate the potential usefulness of CD38
expression as a marker of anti-retroviral drug efficacy.
Results from these initial studies basically show that HIV-1-
infected patients who have received ART and have sustained
plasma viral loads of <50 copies/ml do indeed demonstrate a
somewhat lower frequency of CD8+ T cells which
expressed CD38. However, a decrease in the mean density
of CD38 expression in addition to the use of HLA-DR co-
expression by CD8+ T cells provides a more reliable marker
for therapeutic drug monitoring which is practical and more
cost effective than the techniques outlined above. It should
be noted that the studies reported herein were conducted as a
cross-sectional study and it is highly likely that results of
differences in the co-expression of CD38 and HLA-DR on
CD8+ T cells from patients prior to and post-ART may
provide an even more discriminatory tool.
The stable suppression of HIV replication is considered
the main goal of ART. However, the inability to suppress
viral replication or virological failure is a frequent finding
(Clough et al., 1999; Deeks et al., 1999; Ledergerber et al.,
1999) and has been associated with the presence of drug-
resistant virus (Frenkel and Tobin, 2004). More importantly,
virological failure has not always been associated with a fall
in CD4 cell level which has led to the concept of
‘‘immunovirological discordance’’ (Moroni, 2003). There
are 4 types of discordant responses in patients receiving
ART, three of them based on virological failure associated
with the presence of drug-resistance virus and a decrease (I),
stable (II), or increase (III) in CD4 count which are
described elsewhere (Belec et al., 2000; Kaufmann et al.,
1998; Piketty et al., 1998; Sufka et al., 2003). Based on the
data presented herein, we propose another explanation
related to chronic immune activation as observed by
CD38 expression. ART may suppress CD4+ T cell
activation by the successful elimination of the high
virulence wild-type virus which decreases CD4+ T cell
turnover, thereby resulting in sustained or increased CD4
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treatment interruption in patients with drug-resistant viremia
resulted in an increase in CD4+ T cell activation associated
with decreased CD4 counts (Deeks et al., 2002). Accord-
ingly, it is possible that patients with type I discordant
response in fact were experiencing a failure in immune
activation control instead of a role for direct pathogenicity
from drug-resistant virus. The effect of immune activation
on the failure to lead to an increase in CD4 counts (type IV
discordant response) in the patients that control viremia but
do not show an increase in CD4 counts (Kaufmann et al.,
2002; Valdez et al., 2002) may be explained by two studies
that showed high levels of T cell activation despite
successful viral suppression (Anthony et al., 2003; Hunt et
al., 2003). These data suggest that immune activation is
central to the depletion of CD4+ T cells in HIV-infected
patients and support the concept of using the analysis of
CD38 expression for the monitoring of patients receiving
ART. Studies aimed at analyzing data on CD38 expression
from such groups of HIV-1-infected patients is the aim of
our future studies.Materials and methods
Study population and sample collection
Peripheral blood samples were obtained from otherwise
normal healthy individuals and HIV-infected patients. Each
study volunteer was explained the nature of the study in the
Thai language and appropriate informed consent was
obtained prior to their enrollment in the study. The study
was approved by the Ethics Committee of the Faculty of
Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand. Thirty-one local healthy adult Thai volunteers
were recruited from laboratory staff of the hospital.
Samples from 20 of these volunteers were used for baseline
studies and all additional studies were conducted with an
additional 11 volunteer samples. The HIV-1-infected
patients were recruited from the HIV Clinic of the Faculty
of Medicine Siriraj Hospital, Mahidol University, Bangkok,
Thailand. The patients were divided into 3 groups, the first
group (n = 20) consisted of patients who did not receive
any ART prior to and during the course of this study, the
second group (n = 23) consisted of HIV-infected patients
who had been on ART for at least 6 months and showed
significant response to therapy, and the third group (n = 5)
consisted of HIV-infected patients who had been on ARTTable 2
Values of CD4+ T cell subsets and viral load
Group Absolute CD4 count (cel
Healthy individuals (n = 31) 781 T 276
Untreated group (n = 20) 381 T 415
Successive ART-treated group (n = 23) 352 T 216
Virological failure group (n = 5) 212 T 263for the same time period but showed virological failure
(viral load >50 copies/ml). Blood samples were collected in
EDTA containing vacutainer tubes. Routine CBC-based
absolute lymphocyte counts and CD4 T cell subset analysis
by flow cytometry were determined on aliquots of a blood
sample from each volunteer (Table 2). Plasma samples were
also collected by centrifugation of an aliquot of each blood
sample and kept at 70 -C and used in batches for viral
load determination.
Monoclonal antibodies and reagents
The following anti-human monoclonal antibodies (mAbs)
and their conjugated fluorochromes were commercially
obtained from Becton Dickinson Biosciences (BDB: San
Jose, CA) and utilized at the concentration recommended by
the manufacturer: anti-human HLA-DR, clone L243, con-
jugated with fluorescein isothiocyanate (FITC) or phycoer-
ythrin (PE); anti-human CD38, clone HB7, conjugated with
FITC or PE; anti-human CD4, clone SK3, conjugated with
allophycocyanin (APC), anti-human CD8, clone SK1, con-
jugated with peridinin chlorophyll protein (PerCP); anti-
human CD3, clone SK7, conjugated with FITC, PE or PerCP;
anti-human CD19, clone 4G7, conjugated with FITC; anti-
human CD56, clone SNCAM16.2, conjugated with APC and
anti-human gy TCR, clone B1, conjugated with APC.
Immunofluorescent staining
The whole blood procedure was utilized for flow
cytometric studies. Aliquots of 50 Al of EDTA blood were
incubated with the following combination of mAbs: Either
CD3 or HLA DR-FITC/CD38-PE/CD8-PerCP/CD4-APC;
and CD38-FITC/CD3 or HLA-DR-PE/CD8-PerCP/CD4-
APC. After the addition of the monoclonal antibody
reagents, samples were gently mixed by vortex, and
incubated in the dark at 25 -C for 15 min followed by the
addition of 1 ml of FACS lysing solution in order to lyse the
red blood cells. The stained samples were gently mixed
again by vortex, and incubated in the dark at 25 -C for 10
min. Following centrifugation at 1200 rpm for 5 min at
room temperature, the supernatant was discarded and the
cell pellet resuspended in 2 ml of wash buffer (PBS with 2%
fetal bovine serum) followed by centrifugation at 1200 rpm
for 5 min at 25 -C. Finally, the cell pellet was resuspended
in 300 Al of freshly prepared 1% paraformaldehyde in PBS
pH 7.4 and subjected to flow analysis. To determine the
frequency of CD38 expressing cells within the lymphocytels/Al) % CD4 Viral load (copies/ml)
37.96 T 8.65 N/A
17.09 T 11.78 76,658 T 81,324
16.99 T 8.42 <50
10.47 T 10.43 165,269 T 198,908
N. Onlamoon et al. / Virology 341 (2005) 238–247246subsets, the following combination of mAbs were used:
CD19-FITC/CD38-PE/ CD3-PerCP/CD56-APC and CD19-
FITC/CD38-PE/CD3-PerCP/gy TCR-APC.
Flow cytometric analysis
Six-parameter analysis was performed on a FACSCaliber
flow cytometer (BDB) using CellQuest software (BDB).
Cells were gated using lymphogate for the analysis of only
viable cells and at least 30,000 viable cells were analyzed per
sample. The frequency of CD4+ or CD8+ T cells was
identified by gating on either CD4 or CD8 vs. a side scatter
dot plot. Only the CD8+ bright population was used for
analysis since this population was previously identified as
cells enriched for those expressing the CD8 alpha/beta
heterodimer as compared with the low-density CD8 express-
ing cells that are predominantly alpha chain homodimer
positive and likely represent a NK cell subset. The frequency
(percentage) and density (mean fluorescent intensity, MFI)
of CD38 expressing subsets of cells were determined utilzing
a histogram plot whereas the percentage of the CD38+ HLA-
DR+ cells were determined by two-color dot plot (FITC vs.
PE) analysis. Isotype controls were used to define the
positive and negative population.
Viral load measurement
HIV viral loads were determined by the automated
Amplicor polymerase chain reaction (PCR) (CoBas Ampli-
cor HIV-1 monitor test version 1.5; Roche Diagnostic). The
sensitivity of detection by this assay was determined to be
400 HIV copies/ml of plasma utilizing the standard assay
and 50 HIV copies/ml of plasma utilizing the ultrasensitive
assay.
Statistical analysis
Data for each assay are presented as mean T SD of
sample. The Mann–Whitney U test was used to determine
the statistical significance of the difference observed
between groups. The Pearson correlation coefficient test
was used to analyze for the association observed between
different parameters. P values <0.05 was considered
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